UK markets closed

NIKKEI 225
38,385.73
+29.67(+0.08%)
HANG SENG
19,073.71
-41.35(-0.22%)
CRUDE OIL
78.85
+0.83(+1.06%)
GOLD FUTURES
2,392.20
+32.30(+1.37%)
DOW
39,908.00
+349.89(+0.88%)
Bitcoin GBP
51,945.96
+3,400.43(+7.00%)

How to claim expenses at work without breaking the rules

Knowing more about tax rules can save you money

GILD May 2024 78.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.1800

0.0000

(0.00%)

As of 09:30AM EDT. Market open.

Business Wire
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
Yahoo Finance
One stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
Zacks
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.